ECC-5004 is under clinical development by Eccogene (Shanghai) and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ECC-5004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ECC-5004 is under development for the treatment of non-alcoholic steatohepatitis (NASH), obesity and Type 2 diabetes. It acts by targeting glucagon like peptide (GLP)-1 receptor and it is administered through oral route.
Eccogene (Shanghai) overview
Eccogene (Shanghai) is a biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. It is headquartered in Shanghai, China.
For a complete picture of ECC-5004’s drug-specific PTSR and LoA scores, buy the report here.